TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Able to comprehend and follow the requirements of the study (including availability on scheduled visit dates) based upon research site personnel's assessment;~2. Caregiver is able and willing to provide written informed consent for the participant to participate in the trial;~3. Male or female of any race or ethnicity, 2 months to 35 months of age;~4. Diagnosed as having Atopic Dermatitis (AD) on the basis of the criteria defined by Hanifin and Rajka~5. Rated as having mild to moderate AD (graded between 3.0 and 7.5 inclusive) as per Rajka-Langeland severity index~6. Willing to stop all emollients, moisturizers and/or other skin barrier cream or emulsion treatments for the AD condition during the test period. If using corticosteroids (not Class I, II, or III) or immunomodulators at study entry, must be on a stable dose for a minimum of 1 month;~7. Willing to undergo a washout period of 2 days before the trial initiation where no use of moisturizers or emollients will be allowed; and~8. Willing and able to comply with scheduled visits, treatment plan, and other trial procedures.~Exclusion Criteria:~1. Known sensitivity to any investigational product ingredient;~2. Use of a therapeutic (over the counter or prescription) body wash that contains an active ingredient for eczema;~3. Participation in any clinical study within 30 days of Visit 1;~4. Relative, partner or staff of any clinical research site personnel;~5. Active infection of any type at the start of the study;~6. Severe AD as determined by the Rajka-Langeland Severity Index~7. AD requiring systemic, super-potent (Class I) or potent (Class II or III) topical corticosteroids. If a participant requires any of these medications as rescue therapy during the study, the participant will be discontinued from the trial;~8. Requires any inhaled or intranasal corticosteroids;~9. Other medical condition that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 35 Months
- Healthy Volunteers: f

Study Arms:
- EPI (Type: ACTIVE_COMPARATOR): None
- NEE (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years or older~* Atopic dermatitis involvement that of at least 10% body surface area~Exclusion Criteria:~* Treatment with systemic corticosteroids within 4 weeks before randomization, and topical steroids, tacrolimus and/or pimecrolimus within 1 week before the randomization (except emollients, and mild steroids (class 6 or 7)~* Any cell-depleting agents including but not limited to rituximab: within 6 months prior to the baseline visit or until lymphocyte and CD 19+ lymphocyte counts return to normal, whichever is longer. Other biologics: within 5 half-lives or 8 weeks prior to the baseline visit, whichever is longer. Allergen immunotherapy within 6 months before the baseline visit.~* Patient with history of serious local infection and systemic infection Patient with history or current evidence of diseases such as tuberculosis, malignant disease, other inflammatory or autoimmune disease or HIV or Hepatitis B or C positive.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GBR 830 (Type: EXPERIMENTAL): Two doses of GBR 830, 10 mg/kg (solution for infusion, prepared in normal saline) administered intravenously (IV) four weeks apart.
- Placebo (Type: PLACEBO_COMPARATOR): Two doses of placebo (formulation buffer for infusion, prepared in normal saline) administered IV four weeks apart.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com~Inclusion Criteria:~* Body Mass Index (BMI) of 18.0 to 33.0 kg/m\^2, inclusive. BMI = weight (kg)/(height \[m\])\^2~* Healthy based on medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG) at screening and check-in~Exclusion Criteria:~* Allergy to or hypersensitive to any of the drugs or nutritional supplement used in the study~* Prior history of Wernicke's Encephalopathy~* Thiamine deficiency~* Hypersensitivity to ondansetron~* Has any medical condition, medical history, or use of concomitant medication that is contraindicated in the applicable drug labeling~* Has history, deviated nasal septum, and/or obstructed airway, bleeding disorders, or other inabilities for insertion of nasogastric (NG) tube (Part 2 only)~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Treatment 1A (Type: EXPERIMENTAL): None
- Treatment 1B (Type: EXPERIMENTAL): None
- Treatment 2A (Type: EXPERIMENTAL): None
- Treatment 2B (Type: EXPERIMENTAL): None
- Treatment 2C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histopathologically confirmed glioblastoma multiforme~  * Grade IV disease by WHO classification~ * Newly diagnosed disease~* Initial diagnostic surgery or biopsy performed within the past 4 weeks~* Not a candidate for standard radiotherapy (60Gy/30 fractions over 6 weeks) in combination with temozolomide~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute granulocyte count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Bilirubin ≤ 1.5 times ULN~* ALT and AST \< 2.5 times ULN~* No known hypersensitivity to temozolomide or compounds with similar chemical composition to temozolomide~* No history of other malignancies except adequately treated nonmelanoma skin cancer, curatively treated in situ cancer of the cervix, or other curatively treated solid tumors with no evidence of disease for at least 5 years~* No serious active infection (e.g., wound infection requiring parenteral antibiotics) or other serious underlying medical conditions that would preclude study treatment~* No other condition (e.g., psychological or geographical) that would preclude study compliance~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy~* No prior radiotherapy~* No prior or concurrent investigational therapy~* No concurrent surgical procedures for tumor debulking~* No concurrent stereotactic boost radiotherapy~* No other concurrent chemotherapy, immunotherapy, or biological therapy~* No concurrent epoetin alfa~* Concurrent corticosteroids allowed provided the patient has been on a stable or decreasing dose for at least 14 days

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Temozolomide (Type: ACTIVE_COMPARATOR): Temozolomide and short course radiation
- Radiation (Type: ACTIVE_COMPARATOR): Short course radiation alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3, 2018.~* Age of the participant at the time of migraine onset \< 50 years -History of 4 to 14 migraine days per month on average in the 3 months prior to Visit 1 in the investigator's judgment~* Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period.~* 4 to 14 migraine days in the 28-day baseline period per eDiary~* Failed oral migraine prophylaxis medications from 2 to 4 medication classes~Exclusion Criteria:~* Any clinically significant hematologic, endocrine, pulmonary, hepatic, gastrointestinal, or neurologic disease~* Participant has any other concurrent pain condition that, in the opinion of the investigator, may significantly impact the current headache disorder~* In the opinion of the investigator, confounding psychiatric conditions, dementia, epilepsy, or significant neurological disorders other than migraine~* Has ≥ 15 headache days per month on average across the 3 months prior to Visit 1 in the investigator's judgment~* Has ≥ 15 headache days in the 28-day baseline period per eDiary~* Clinically significant cardiovascular or cerebrovascular disease~* Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine as defined by ICHD-3, 2018~* Has a current diagnosis of chronic migraine, new persistent daily headache, medication overuse headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3, 2018

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received atogepant-matching placebo tablets, orally, once daily (QD) for up to 12 weeks in a double-blind (DB) treatment period.
- Atogepant 60 mg (Type: ACTIVE_COMPARATOR): Participants received atogepant 60 mg, orally, QD for up to 12 weeks in a DB treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone Versus Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women aged 18-45 having pregnancy termination at 14-16 weeks~Exclusion Criteria:~* multiple gestation, pre-existing infection, contraindication to osmotic dilators, unable to obtain proper consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- mifepristone (Type: EXPERIMENTAL): women in the mifepristone are would take mifepristone 200 mg for cervical preparation the day before their procedure, and not have dilators inserted. In this group, the sstandard procedure of osmotic dilator insertion is NOT performed.
- Osmotic dilator insertion (Type: ACTIVE_COMPARATOR): Women assigned to this arm would have the standard procedure for cervical preparation, which is insertion of osmotic dilators the day before the abortion procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye treated with (OZURDEX®) in clinical practice.~Exclusion Criteria:~* Patients with eye infections~* Patients with glaucoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OZURDEX® (Type: None): Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Stage III to V Chronic Kidney Disease~* Serum Phosphorus 4.0-6.0 mg/dL prior to Randomization~* Ferritin 300 ng/mL or less~* Transferrin Saturation (TSAT) 30% or less~* Hemoglobin \>9.0 and \<12.0 g/dL~* Must consume a minimum of 2 meals per day~Exclusion Criteria:~* Parathyroidectomy within 24 weeks of study~* gastrointestinal bleed or inflammatory bowel disease within 12 weeks of study~* Requirement for dialysis or kidney injury within 8 weeks of study~* Absolute requirement for oral iron, intravenous iron, Erythropoiesis-Stimulating Agent, blood transfusions, and Sensipar during the study~* Absolute requirement for calcium-, magnesium-, or aluminum-containing drugs with meals~* Absolute requirement for vitamin C, niacin, or nicotinamide outside of multivitamins~* History of hemochromatosis~* Allergy to iron products~* History of malignancy in last 5 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Citrate (Type: EXPERIMENTAL): Ferric citrate will be taken with or within one hour of meals or snacks. The starting dose of ferric citrate is 3 tablets/day and titrated by the subject's serum phosphorus results at each treatment visit.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be taken with or within one hour of meals or snacks. The starting dose of placebo is 3 tablets per day and titrated by the subject's serum phosphorus results at each treatment visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children aged 6 months to \< 6 years who have been treated for at least 2 months or, in case of catheter related thrombosis, for at least 6 weeks with LMWH (low molecular weight heparin), fondaparinux and/or VKA (vitamin K antagonist) for documented symptomatic or asymptomatic venous thrombosis - Hemoglobin, platelets, creatinine, alanine aminotransferase (ALT) and bilirubin evaluated within 10 days prior to randomization~* Informed consent provided~Exclusion Criteria:~* Active bleeding or high risk for bleeding contraindicating anticoagulant therapy~* Symptomatic progression of venous thrombosis during preceding anticoagulant treatment~* Planned invasive procedures, including lumbar puncture and removal of non peripherally placed central lines during study treatment~* An estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m\^2~* Hepatic disease which is associated with either: coagulopathy leading to a clinically relevant bleeding risk, or ALT\> 5x upper level of normal (ULN) or total bilirubin \> 2x ULN with direct bilirubin \> 20% of the total~* Platelet count \< 50 x 10\*9/L~* Hypertension defined as \> 95th age percentile~* Life expectancy \< 3 months~* Concomitant use of strong inhibitors of both cytochrome P450 isoenzyme 3A4 (CYP3A4) and P-glycoprotein (P-gp), i.e. all human immunodeficiency virus protease inhibitors and the following azole antimycotics agents: ketoconazole, itraconazole, voriconazole, posaconazole, if used systemically~* Concomitant use of strong inducers of CYP3A4, i.e. rifampicin, rifabutin, phenobarbital, phenytoin and carbamazepine~* Hypersensitivity or any other contraindication listed in the local labeling for the comparator treatment or experimental treatment~* Inability to cooperate with the study procedures~* Previous randomization to this study~* Participation in a study with an investigational drug or medical device within 30 days prior to randomization

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Age and body weight-adjusted twice daily dosing of rivaroxaban to achieve a similar exposure as that observed in adults treated for venous thromboembolism (VTE) with 20 mg rivaroxaban once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women aged 18-45 with a viable single or twin intrauterine pregnancy between 22 0/7 and 41 6/7 weeks gestation based on the best obstetric estimate by The American College of Obstetricians and Gynecologists (ACOG) criteria.~* Diagnosis of preeclampsia with severe features with decision made to induce labor. The patient may or may not have already received acute treatment for severe blood pressures.~Exclusion Criteria:~* Known allergy or adverse reaction to Nifedipine or any medical condition where Nifedipine is contraindicated, such as galactose intolerance, severe gastrointestinal (GI) structure, and GI hypomotility disorder.~* Currently receiving Nifedipine XL as part of hypertension management prior to induction of labor~* Participation in another trial that affects the primary outcome without prior approval~* Physician/provider or patient refusal~* Participation in this trial in a prior pregnancy~* Triplet or higher order pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Nifedipine 30MG (Type: ACTIVE_COMPARATOR): Oral administration of 30mg Nifedipine XL q24 hours until delivery
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo group q24hrs until delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Spread of Transversus Abdominis Plane Block

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* undergo abdominal surgery, eligible for TAP block, over 18, BMI 20-40~Exclusion Criteria:~* does not speak danish, does not consent, does not fulfill inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- TAP block (Type: None): Patients before undergoing laparoscopic or other abdominal surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-nursing female aged 18 to 75 years old~* Clinical diagnosis of moderate to severe, chronic non-neuropathic low back pain for at least six months~* Not experiencing adequate pain relief or have failed previous treatment with non-opioid analgesics~* Opioid analgesia is necessary~* Currently taking no more than 10 mg morphine sulfate equivalents per day of short acting opioids for 14 days prior to entry~* Females of child bearing potential must be using a highly effective form of birth control. All subjects must agree to use double-barrier contraception during participation in this study and for at least 2 months after the last dose of the study drug.~* Willing and able to provide informed consent~Exclusion Criteria:~* Taking extended release or long-acting opioids within 6 months~* History of hypersensitivity, intolerance, or allergy to opioids~* Compression of spinal nerve root; spinal fracture, tumor, or abscess~* Surgical procedures on the low back in the last 12 months or facet nerve root block or radiofrequency ablation in the last 3 months~* Untreated moderate to severe sleep apnea

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- NKTR-181 (Type: EXPERIMENTAL): NKTR-181 twice daily (BID) tablets
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match NKTR-181 twice daily (BID) tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete